Incyte Aktie News

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Medicine remains one of the most potentially rewarding of all investment areas. And this biotech stock is flirting with a buy point as analysts see earnings skyrocketing.

Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.

Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.

December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, esse...